Incorporation of a Nitric Oxide Donating Motif into Novel PC-PLC Inhibitors Provides Enhanced Anti-Proliferative Activity
Open Access
- 26 October 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21), 11518
- https://doi.org/10.3390/ijms222111518
Abstract
Inhibition of phosphatidylcholine-specific phospholipase C (PC-PLC) has previously been shown to be a potential target for novel cancer therapeutics. One downstream consequence of PC-PLC activity is the activation of NF-κB, a nuclear transcription factor responsible for transcribing genes related to oncogenic traits, such as proliferation, angiogenesis, metastasis, and cancer cell survival. Another biological pathway linked to NF-κB is the exogenous delivery of nitric oxide (NO), which decreases NF-κB activity through an apparent negative-feedback loop. In this study, we designed and synthesised 13 novel NO-releasing derivatives of our previously reported class of PC-PLC inhibitors, 2-morpholinobenzoic acids. These molecules contained a secondary benzylamine group, which was readily nitrosylated and subsequently confirmed to release NO in vitro using a DAF-FM fluorescence-based assay. It was then discovered that these NO-releasing derivatives possessed significantly improved anti-proliferative activity in both MDA-MB-231 and HCT116 cancer cell lines compared to their non-nitrosylated parent compounds. These results confirmed that the inclusion of an exogenous NO-releasing functional group onto a known PC-PLC inhibitor enhances anti-proliferative activity and that this relationship can be exploited in order to further improve the anti-proliferative activity of current/future PC-PLC inhibitors.Funding Information
- Breast Cancer Foundation New Zealand (Ronald Kay Fellowship)
- University of Auckland (Doctoral Scholarship)
This publication has 29 references indexed in Scilit:
- Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cellsBreast Cancer Research, 2012
- Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cellsCancer Biology & Therapy, 2011
- Biochemical aspects of nitric oxide synthase feedback regulation by nitric oxideInterdisciplinary Toxicology, 2011
- Functional roles of PC‐PLC and Cdc20 in the cell cycle, proliferation, and apoptosisCell Biochemistry and Function, 2010
- N-Nitrosation of Secondary Amines Using p-TSA-NaNO2 as a Novel Nitrosating Agent Under Mild ConditionsSynthetic Communications, 2010
- Cell-cycle-dependent PC-PLC regulation by APC/CCdc20-mediated ubiquitin-proteasome pathwayJournal of Cellular Biochemistry, 2009
- Nitric oxide suppresses inducible nitric oxide synthase expression by inhibiting post-translational modification of IκBExperimental & Molecular Medicine, 2004
- Involvement of nuclear factor-κB in lipoteichoic acid-induced cyclooxygenase-2 expression in RAW 264.7 macrophagesJournal of Pharmacy and Pharmacology, 2003
- Induction of Nitric Oxide Synthase mRNA ExpressionOnline Journal of Public Health Informatics, 1995
- TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced “Acidic” sphingomyelin breakdownCell, 1992